gastro-jРоссийский журнал гастроэнтерологии, гепатологии, колопроктологииRussian Journal of Gastroenterology, Hepatology, Coloproctology1382-43762658-6673«Gastro» LLC10.22416/1382-4376-2016-26-1-8-14gastro-j-15Research ArticleЛЕКЦИИ И ОБЗОРЫLECTURES AND REVIEWSПробиотики, метаболизми функциональное состояние сердечно-сосудистой системыProbiotics, metabolism and the functional condition of cardio-vascular systemКашухЕ. А.KashukhYe. A.katrin1.10@mail.ruИвашкинВ. Т.IvashkinV. T.noemail@neicon.ruКлиника пропедевтики внутренних болезней, гастроэнтерологии и гепатологии им. В.Х. Василенко ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова»РоссияVasilenko Clinic of internal diseases propedeutics, gastroenterology and hepatology State educational government-financed institution of higher professional education «Sechenov First Moscow state medical university»Russian Federation201612082016261814Copyright © Кашух Е.А., Ивашкин В.Т., 20162016Кашух Е.А., Ивашкин В.Т.Kashukh Y.A., Ivashkin V.T.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.gastro-j.ru/jour/article/view/15

Цель обзора. Описание предполагаемой связи между микробиомом и структурно-функциональным состоянием сердечно-сосудистой системы. Основные положения. Кроме традиционных представлений о факторах риска развития атеросклероза и сердечно-сосудистых заболеваний необходимо учитывать сведения о новых механизмах формирования данных патологий. Исследования продемонстрировали участие микробиома желудочно-кишечного тракта человека в повышении сердечно-сосудистого риска вследствие выделения микроорганизмами определенных провоспалительных белков и молекул, способствующих как развитию атеросклероза, так и непосредственному поражению сердца и сосудов. Пробиотики, назначающиеся в основном при гастроэнтерологической патологии, также могут быть применены для коррекции факторов риска развития сердечно-сосудистых заболеваний. Полученные данные демонстрируют успехи в терапии атеросклероза, артериальной гипертензии, метаболического синдрома, сердечной недостаточности при приеме определенных пробиотических штаммов. Заключение. Микрофлора может выступать как участник в развитии сердечно-сосудистых заболеваний и атеросклероза вследствие метаболического симбиоза с макроорганизмом. Пробиотики могут оказаться профилактическим средством в устранении метаболических нарушений, приводящих к развитию сердечно-сосудистых заболеваний и атеросклероза.

The aim of review. To characterize possible relation between microbiome and cardio-vascular system structural and functional state. Key points. Along with traditional concepts on the risk factors of atherosclerosis and cardio-vascular diseases development one should take into account data on the new pathogenic mechanisms for these diseases. According to recent studies human gastrointestinal microbiome may increase cardiovascular risk due to bacterial production of proinflammatory proteins that both promote development of atherosclerosis and directly affect the heart and vessels. Probiotics, that are mainly prescribed at gastroenterological diseases, may be applied for correction of cardiovascular risk factors as well. Obtained data demonstrate that intake of certain probiotic strains may be applied as a successful treatment of atherosclerosis, systemic hypertension, metabolic syndrome and heart failure. Conclusion. Microbiome may be involved in development of cardio-vascular diseases and atherosclerosis due to metabolic symbiosis with the host. Probiotics may be applied as preventive medication for correction of metabolic disorders that result in development of cardio-vascular diseases and atherosclerosis.

атеросклерозсердечнососудистые заболеваниямикробиомдислипидемияпробиотикиартериальная гипертензияхроническая сердечная недостаточностьL-карнитиножирениеReferencesWorld Health Organization. Global status report on noncommunicable diseases. 2014; 9-23.World Health Organization. Global status report on noncommunicable diseases. 2014; 9-23.Ettinger G., MacDonald K., Reid G., Burton J.P. The influence of the human microbiome and probiotics on cardiovascular health. Gut Microbes 2014; 5(6):719-28.Ettinger G., MacDonald K., Reid G., Burton J.P. The influence of the human microbiome and probiotics on cardiovascular health. Gut Microbes 2014; 5(6):719-28.Marijon E., Mirabel M., Celermajer D.S., Jouven X. Rheumatic heart disease. Lancet 2012; 379:953-64.Marijon E., Mirabel M., Celermajer D.S., Jouven X. Rheumatic heart disease. Lancet 2012; 379:953-64.Ford P.J., Gemmell E., Hamlet S.M., Hasan A., Waler P.J., West M.J., Cullinan M.P., Seymour G.J. Cross-reactivity of GroEL antibodies with human heat shock protein 60 and quantification of pathogens in atherosclerosis. Oral Microbiol Immunol 2005; 20:296-302.Ford P.J., Gemmell E., Hamlet S.M., Hasan A., Waler P.J., West M.J., Cullinan M.P., Seymour G.J. Cross-reactivity of GroEL antibodies with human heat shock protein 60 and quantification of pathogens in atherosclerosis. Oral Microbiol Immunol 2005; 20:296-302.Haraszthy V.I., Zambon J.J., Trevisan M., Zeid M., Genco R.J. Identification of periodontal pathogens in atheromatous plaques. J Periodontol 2000; 71:1554-60.Haraszthy V.I., Zambon J.J., Trevisan M., Zeid M., Genco R.J. Identification of periodontal pathogens in atheromatous plaques. J Periodontol 2000; 71:1554-60.Koeth R.A., Wang Z., Levison B.S., Buffa J.A., Org E., et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19:576-85.Koeth R.A., Wang Z., Levison B.S., Buffa J.A., Org E., et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 2013; 19:576-85.Tang W.H., Wang Z., Wu Yu., Fan Y., Kocth R.A., Hazen S.L. Gut flora metabolite trimethylamine N-oxide predicts incident cardiovascular risks in both stable nondiabetics and diabetic subjects. JACC 2013; 61(10).Tang W.H., Wang Z., Wu Yu., Fan Y., Kocth R.A., Hazen S.L. Gut flora metabolite trimethylamine N-oxide predicts incident cardiovascular risks in both stable nondiabetics and diabetic subjects. JACC 2013; 61(10).Wang Z., Klipfell E., Bennett B.J., Koeth R., Levison B.S., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472:57-63.Wang Z., Klipfell E., Bennett B.J., Koeth R., Levison B.S., et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 2011; 472:57-63.Koeth R.A., Levison B.S., Culley M.K., Wang Z., Buffa A. γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. MK Cell Metab 2014; 20(5):799-812.Koeth R.A., Levison B.S., Culley M.K., Wang Z., Buffa A. γ-Butyrobetaine is a proatherogenic intermediate in gut microbial metabolism of L-carnitine to TMAO. MK Cell Metab 2014; 20(5):799-812.Food and Agriculture Association on the United Nations, World Health Organization. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria 2001. FAO FeoD and Nutrition paper N 85. P. 15-7.Food and Agriculture Association on the United Nations, World Health Organization. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria 2001. FAO FeoD and Nutrition paper N 85. P. 15-7.Reid G., Beuerman D., Heinemann C., Bruce A.W. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Immunol Med Microbiol 2001; 32:37-41.Reid G., Beuerman D., Heinemann C., Bruce A.W. Probiotic Lactobacillus dose required to restore and maintain a normal vaginal flora. FEMS Immunol Med Microbiol 2001; 32:37-41.Ruszczynski M., Radzikowski A., Szajewska H. Clinical trial: Effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibioticassociated diarrhoea in children. Aliment Pharmacol Ther 2008; 28:154-61.Ruszczynski M., Radzikowski A., Szajewska H. Clinical trial: Effectiveness of Lactobacillus rhamnosus (strains E/N, Oxy and Pen) in the prevention of antibioticassociated diarrhoea in children. Aliment Pharmacol Ther 2008; 28:154-61.McFarland L.V., Surawicz C.M., Greenberg R.N., Fekety R., Elmer G.W., Moyer K.A., Melcher S.A., Bowen K.E., Cox J.L., Noorani Z., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913-8.McFarland L.V., Surawicz C.M., Greenberg R.N., Fekety R., Elmer G.W., Moyer K.A., Melcher S.A., Bowen K.E., Cox J.L., Noorani Z., et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271:1913-8.Ducrotte P., Sawant P., Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 2012; 18:4012-8.Ducrotte P., Sawant P., Jayanthi V. Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 2012; 18:4012-8.Walker W.A. Mechanisms of action of probiotics. Clin Infect Dis 2008; 46:87-91.Walker W.A. Mechanisms of action of probiotics. Clin Infect Dis 2008; 46:87-91.Teughels W., Durukan A., Ozcelik O., Pauwels M., Quirynen M., Haytac M.C. Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: A randomized placebo-controlled study. J Clin Periodontol 2013; 40:1025-35.Teughels W., Durukan A., Ozcelik O., Pauwels M., Quirynen M., Haytac M.C. Clinical and microbiological effects of Lactobacillus reuteri probiotics in the treatment of chronic periodontitis: A randomized placebo-controlled study. J Clin Periodontol 2013; 40:1025-35.Hyde E.R., Andrade F., Vaksman Z., Parthasarathy K., Jiang H., Parthasarathy D.K., Torregrossa A.C., Tribble G., Kaplan H.B., Petrosino J.F., et al. Metagenomic analysis of nitrate-reducing bacteria in the oral cavity: Implications for nitric oxide homeostasis. PLoS One 2014; 9(3):e88645.Hyde E.R., Andrade F., Vaksman Z., Parthasarathy K., Jiang H., Parthasarathy D.K., Torregrossa A.C., Tribble G., Kaplan H.B., Petrosino J.F., et al. Metagenomic analysis of nitrate-reducing bacteria in the oral cavity: Implications for nitric oxide homeostasis. PLoS One 2014; 9(3):e88645.Drapkina O.M., Korneeva O.N., Ivashkin V.T. Dietary intervention in patients with metabolic syndrome: short-effects on abdominal obesity. Arterial Hypertension 2009; 15(3):275-9.Drapkina O.M., Korneeva O.N., Ivashkin V.T. Dietary intervention in patients with metabolic syndrome: short-effects on abdominal obesity. Arterial Hypertension 2009; 15(3):275-9.Lee S.J., Bose S., Seo J.G., Chung W.S., Lim C.Y., Kim H. The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis: A randomized double-blind controlled clinical trial. Clin Nutr 2014 Dec; 33(6)973-81.Lee S.J., Bose S., Seo J.G., Chung W.S., Lim C.Y., Kim H. The effects of co-administration of probiotics with herbal medicine on obesity, metabolic endotoxemia and dysbiosis: A randomized double-blind controlled clinical trial. Clin Nutr 2014 Dec; 33(6)973-81.Silveira M.B., Carraro R., Monereo S., Tebar J. Conjugated linoleic acid (CLA) and obesity. Public Health Nutr 2007; 10(10A):1181-6.Silveira M.B., Carraro R., Monereo S., Tebar J. Conjugated linoleic acid (CLA) and obesity. Public Health Nutr 2007; 10(10A):1181-6.Hamad E.M., Sato M., Uzu K., Yoshida T., Higashi S., Kawakami H., Kadooka Y., Matsuyama H., Abd El-Gawad I.A., Imaizumi K. Milk fermented by Lactobacillus gasseri SBT2055 influences adipocyte size via inhibition of dietary fat absorption in Zucker rats. Br J Nutr 2009; 101:716-24.Hamad E.M., Sato M., Uzu K., Yoshida T., Higashi S., Kawakami H., Kadooka Y., Matsuyama H., Abd El-Gawad I.A., Imaizumi K. Milk fermented by Lactobacillus gasseri SBT2055 influences adipocyte size via inhibition of dietary fat absorption in Zucker rats. Br J Nutr 2009; 101:716-24.Kumar M., Nagpal R., Kumar R., Hemalatha R., Verma V., Kumar A., Chakraborty C., Singh B., Marotta F., Jain S., et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res 2012; 2012:902-17.Kumar M., Nagpal R., Kumar R., Hemalatha R., Verma V., Kumar A., Chakraborty C., Singh B., Marotta F., Jain S., et al. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Exp Diabetes Res 2012; 2012:902-17.Dong J.Y., Szeto I.M., Makinen K., Gao Q., Wang J., Qin L.Q., Zhao Y. Effect of probiotic fermented milk on blood pressure: A meta-analysis of randomised controlled trials. Br J Nutr 2013; 110:1188-94.Dong J.Y., Szeto I.M., Makinen K., Gao Q., Wang J., Qin L.Q., Zhao Y. Effect of probiotic fermented milk on blood pressure: A meta-analysis of randomised controlled trials. Br J Nutr 2013; 110:1188-94.Yeo S.K., Liong M.T. Angiotensin I-converting enzyme inhibitory activity and bioconversion of isoflavones by probiotics in soymilk supplemented with prebiotics. Int J Food Sci Nutr 2010; 61:161-81.Yeo S.K., Liong M.T. Angiotensin I-converting enzyme inhibitory activity and bioconversion of isoflavones by probiotics in soymilk supplemented with prebiotics. Int J Food Sci Nutr 2010; 61:161-81.Gan X.T., Ettinger G., Huang C.X., Burton J.P., Haist J.V., Rajapurohitam V., Sidaway J.E., Martin G., Gloor G.B., Swann J.R., et al. Probiotic administration attenuates myocardial hypertrophy and heart failure following myocardial infarction in the rat. Circ Heart Fail 2014; 7:491-9.Gan X.T., Ettinger G., Huang C.X., Burton J.P., Haist J.V., Rajapurohitam V., Sidaway J.E., Martin G., Gloor G.B., Swann J.R., et al. Probiotic administration attenuates myocardial hypertrophy and heart failure following myocardial infarction in the rat. Circ Heart Fail 2014; 7:491-9.Gaci N., Borrel G., Tottey W., O’Toole P.W., Brugère J. Archaea and the human gut: new beginning of an old story. World J Gastroenterol 2014; 20(43):16062-78.Gaci N., Borrel G., Tottey W., O’Toole P.W., Brugère J. Archaea and the human gut: new beginning of an old story. World J Gastroenterol 2014; 20(43):16062-78.Brugère J.F., Borrel G., Gaci N., Tottey W. Archaebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease. Gut Microbes 2014; 5(1):5-10.Brugère J.F., Borrel G., Gaci N., Tottey W. Archaebiotics: proposed therapeutic use of archaea to prevent trimethylaminuria and cardiovascular disease. Gut Microbes 2014; 5(1):5-10.

The authors declare that there are no conflicts of interest present.